Payman Zamani1, Victor Tan2, Haideliza Soto-Calderon2, Melissa Beraun2, Jeffrey A Brandimarto2, Lien Trieu2, Swapna Varakantam2, Paschalis-Thomas Doulias2, Raymond R Townsend2, Jesse Chittams2, Kenneth B Margulies2, Thomas P Cappola2, David C Poole2, Harry Ischiropoulos2, Julio A Chirinos2. 1. From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.). pzamani@upenn.edu. 2. From the Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (P.Z., V.T., H.S.-C., M.B., J.A.B., S.V., K.B.M., T.P.C., J.A.C.); Rowan University School of Osteopathic Medicine, Stratford, NJ (L.T.); Children's Hospital of Philadelphia Research Institute, PA (P.-T.D., H.I.); Division of Nephrology/Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Office of Nursing Research, School of Nursing, University of Pennsylvania, Philadelphia (J.C.); Departments of Kinesiology, Anatomy, and Physiology, Kansas State University, Manhattan (D.C.P.).
Abstract
RATIONALE: Nitrate-rich beetroot juice has been shown to improve exercise capacity in heart failure with preserved ejection fraction, but studies using pharmacological preparations of inorganic nitrate are lacking. OBJECTIVES: To determine (1) the dose-response effect of potassium nitrate (KNO3) on exercise capacity; (2) the population-specific pharmacokinetic and safety profile of KNO3 in heart failure with preserved ejection fraction. METHODS AND RESULTS: We randomized 12 subjects with heart failure with preserved ejection fraction to oral KNO3 (n=9) orpotassium chloride (n=3). Subjects received 6 mmol twice daily during week 1, followed by 6 mmol thrice daily during week 2. Supine cycle ergometry was performed at baseline (visit 1) and after each week (visits 2 and 3). Quality of life was assessed with the Kansas City Cardiomyopathy Questionnaire. The primary efficacy outcome, peak O2-uptake, did not significantly improve (P=0.13). Exploratory outcomes included exercise duration and quality of life. Exercise duration increased significantly with KNO3 (visit 1: 9.87, 95% confidence interval [CI] 9.31-10.43 minutes; visit 2: 10.73, 95% CI 10.13-11.33 minute; visit 3: 11.61, 95% CI 11.05-12.17 minutes; P=0.002). Improvements in the Kansas City CardiomyopathyQuestionnaire total symptom (visit 1: 58.0, 95% CI 52.5-63.5; visit 2: 66.8, 95% CI 61.3-72.3; visit 3: 70.8, 95% CI 65.3-76.3; P=0.016) and functional status scores (visit 1: 62.2, 95% CI 58.5-66.0; visit 2: 68.6, 95% CI 64.9-72.3; visit 3: 71.1, 95% CI 67.3-74.8; P=0.01) were seen after KNO3. Pronounced elevations in trough levels of nitric oxide metabolites occurred with KNO3 (visit 2: 199.5, 95% CI 98.7-300.2 μmol/L; visit 3: 471.8, 95% CI 377.8-565.8 μmol/L) versus baseline (visit 1: 38.0, 95% CI 0.00-132.0 μmol/L; P<0.001). KNO3 did not lead to clinically significant hypotension or methemoglobinemia. After 6 mmol of KNO3, systolic blood pressure was reduced by a maximum of 17.9 (95% CI -28.3 to -7.6) mm Hg 3.75 hours later. Peak nitric oxide metabolites concentrations were 259.3 (95% CI 176.2-342.4) μmol/L 3.5 hours after ingestion, and the median half-life was 73.0 (interquartile range 33.4-232.0) minutes. CONCLUSIONS:KNO3 is potentially well tolerated and improves exercise duration and quality of life in heart failure with preserved ejection fraction. This study reinforces the efficacy of KNO3 and suggests that larger randomized trials are warranted. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02256345.
RCT Entities:
RATIONALE: Nitrate-rich beetroot juice has been shown to improve exercise capacity in heart failure with preserved ejection fraction, but studies using pharmacological preparations of inorganic nitrate are lacking. OBJECTIVES: To determine (1) the dose-response effect of potassium nitrate (KNO3) on exercise capacity; (2) the population-specific pharmacokinetic and safety profile of KNO3 in heart failure with preserved ejection fraction. METHODS AND RESULTS: We randomized 12 subjects with heart failure with preserved ejection fraction to oral KNO3 (n=9) or potassium chloride (n=3). Subjects received 6 mmol twice daily during week 1, followed by 6 mmol thrice daily during week 2. Supine cycle ergometry was performed at baseline (visit 1) and after each week (visits 2 and 3). Quality of life was assessed with the Kansas City Cardiomyopathy Questionnaire. The primary efficacy outcome, peak O2-uptake, did not significantly improve (P=0.13). Exploratory outcomes included exercise duration and quality of life. Exercise duration increased significantly with KNO3 (visit 1: 9.87, 95% confidence interval [CI] 9.31-10.43 minutes; visit 2: 10.73, 95% CI 10.13-11.33 minute; visit 3: 11.61, 95% CI 11.05-12.17 minutes; P=0.002). Improvements in the Kansas City Cardiomyopathy Questionnaire total symptom (visit 1: 58.0, 95% CI 52.5-63.5; visit 2: 66.8, 95% CI 61.3-72.3; visit 3: 70.8, 95% CI 65.3-76.3; P=0.016) and functional status scores (visit 1: 62.2, 95% CI 58.5-66.0; visit 2: 68.6, 95% CI 64.9-72.3; visit 3: 71.1, 95% CI 67.3-74.8; P=0.01) were seen after KNO3. Pronounced elevations in trough levels of nitric oxide metabolites occurred with KNO3 (visit 2: 199.5, 95% CI 98.7-300.2 μmol/L; visit 3: 471.8, 95% CI 377.8-565.8 μmol/L) versus baseline (visit 1: 38.0, 95% CI 0.00-132.0 μmol/L; P<0.001). KNO3 did not lead to clinically significant hypotension or methemoglobinemia. After 6 mmol of KNO3, systolic blood pressure was reduced by a maximum of 17.9 (95% CI -28.3 to -7.6) mm Hg 3.75 hours later. Peak nitric oxide metabolites concentrations were 259.3 (95% CI 176.2-342.4) μmol/L 3.5 hours after ingestion, and the median half-life was 73.0 (interquartile range 33.4-232.0) minutes. CONCLUSIONS:KNO3 is potentially well tolerated and improves exercise duration and quality of life in heart failure with preserved ejection fraction. This study reinforces the efficacy of KNO3 and suggests that larger randomized trials are warranted. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02256345.
Authors: Scott K Ferguson; Angela A Glean; Clark T Holdsworth; Jennifer L Wright; Alex J Fees; Trenton D Colburn; Thomas Stabler; Jason D Allen; Andrew M Jones; Timothy I Musch; David C Poole Journal: J Cardiovasc Pharmacol Ther Date: 2015-08-12 Impact factor: 2.457
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: Benjamin A Steinberg; Xin Zhao; Paul A Heidenreich; Eric D Peterson; Deepak L Bhatt; Christopher P Cannon; Adrian F Hernandez; Gregg C Fonarow Journal: Circulation Date: 2012-05-21 Impact factor: 29.690
Authors: Kenyatta Cosby; Kristine S Partovi; Jack H Crawford; Rakesh P Patel; Christopher D Reiter; Sabrina Martyr; Benjamin K Yang; Myron A Waclawiw; Gloria Zalos; Xiuli Xu; Kris T Huang; Howard Shields; Daniel B Kim-Shapiro; Alan N Schechter; Richard O Cannon; Mark T Gladwin Journal: Nat Med Date: 2003-11-02 Impact factor: 53.440
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Andrew R Coggan; Joshua L Leibowitz; Ana Kadkhodayan; Deepak P Thomas; Sujata Ramamurthy; Catherine Anderson Spearie; Suzanne Waller; Marsha Farmer; Linda R Peterson Journal: Nitric Oxide Date: 2014-09-06 Impact factor: 4.427
Authors: Andrew M Jones; Scott K Ferguson; Stephen J Bailey; Anni Vanhatalo; David C Poole Journal: Exerc Sport Sci Rev Date: 2016-04 Impact factor: 6.230
Authors: Trenton D Colburn; Scott K Ferguson; Clark T Holdsworth; Jesse C Craig; Timothy I Musch; David C Poole Journal: J Appl Physiol (1985) Date: 2016-10-27
Authors: Barry A Borlaug; Kevin J Anstrom; Gregory D Lewis; Sanjiv J Shah; James A Levine; Gabe A Koepp; Michael M Givertz; G Michael Felker; Martin M LeWinter; Douglas L Mann; Kenneth B Margulies; Andrew L Smith; W H Wilson Tang; David J Whellan; Horng H Chen; Victor G Davila-Roman; Steven McNulty; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: JAMA Date: 2018-11-06 Impact factor: 56.272
Authors: Andrew R Coggan; Seth R Broadstreet; Kiran Mahmood; Deana Mikhalkova; Michael Madigan; Indra Bole; Soo Park; Joshua L Leibowitz; Ana Kadkhodayan; Deepak P Thomas; Dakkota Thies; Linda R Peterson Journal: J Card Fail Date: 2017-09-12 Impact factor: 5.712
Authors: Yogesh N V Reddy; Gregory D Lewis; Sanjiv J Shah; Martin LeWinter; Marc Semigran; Victor G Davila-Roman; Kevin Anstrom; Adrian Hernandez; Eugene Braunwald; Margaret M Redfield; Barry A Borlaug Journal: Circ Heart Fail Date: 2017-05 Impact factor: 8.790
Authors: Joshua R Smith; Scott K Ferguson; K Sue Hageman; Craig A Harms; David C Poole; Timothy I Musch Journal: Respir Physiol Neurobiol Date: 2017-10-14 Impact factor: 1.931
Authors: William E Hughes; Nicholas T Kruse; Kenichi Ueda; Andrew J Feider; Satoshi Hanada; Joshua M Bock; Darren P Casey Journal: Eur J Appl Physiol Date: 2020-04-17 Impact factor: 3.078